D M Allen1, I M Onorato, T A Green. 1. HIV Seroepidemiology Branch, Centers for Disease Control (CDC), Atlanta, GA 30333.
Abstract
BACKGROUND: Intravenous drug use has played a key role in the human immunodeficiency virus (HIV) epidemic. Standardized surveillance of HIV infection among intravenous drug users (IVDUs) is needed to determine HIV prevalence rates, to monitor changes in prevalence over time, and to describe behaviors associated with HIV infection. METHODS: In 1987, the Centers for Disease Control began collaborating with state and local health departments to conduct a national program of HIV seroprevalence surveys in a variety of populations and settings. This program includes unlinked HIV seroprevalence surveys in IVDUs entering sentinel drug treatment programs. RESULTS: From April 1988 through December 1989, annual studies were completed in 59 drug treatment centers in 33 US cities. Center-specific seroprevalence rates ranged from 0% to 48.2%, with a median of 4.6%. HIV seroprevalence rates varied widely by geographic area, with rates highest in the Northeast, intermediate in the Middle Atlantic cities of Baltimore and Washington, DC, and lower in other parts of the country. Median rates were 15.6% among African Americans, 3.2% among Hispanics, and 3.3% among Whites. CONCLUSIONS: Intravenous drug use is likely to remain an important factor in HIV transmission. This study supports the need to develop or expand programs to prevent the further introduction and spread of HIV among IVDUs and to prevent HIV transmission to their sexual partners.
BACKGROUND: Intravenous drug use has played a key role in the human immunodeficiency virus (HIV) epidemic. Standardized surveillance of HIV infection among intravenous drug users (IVDUs) is needed to determine HIV prevalence rates, to monitor changes in prevalence over time, and to describe behaviors associated with HIV infection. METHODS: In 1987, the Centers for Disease Control began collaborating with state and local health departments to conduct a national program of HIV seroprevalence surveys in a variety of populations and settings. This program includes unlinked HIV seroprevalence surveys in IVDUs entering sentinel drug treatment programs. RESULTS: From April 1988 through December 1989, annual studies were completed in 59 drug treatment centers in 33 US cities. Center-specific seroprevalence rates ranged from 0% to 48.2%, with a median of 4.6%. HIV seroprevalence rates varied widely by geographic area, with rates highest in the Northeast, intermediate in the Middle Atlantic cities of Baltimore and Washington, DC, and lower in other parts of the country. Median rates were 15.6% among African Americans, 3.2% among Hispanics, and 3.3% among Whites. CONCLUSIONS: Intravenous drug use is likely to remain an important factor in HIV transmission. This study supports the need to develop or expand programs to prevent the further introduction and spread of HIV among IVDUs and to prevent HIV transmission to their sexual partners.
Authors: T S Jones; D M Allen; I M Onorato; L R Petersen; T J Dondero; M Pappaioanou Journal: Public Health Rep Date: 1990 Mar-Apr Impact factor: 2.792
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: M Pappaioanou; T J Dondero; L R Petersen; I M Onorato; C D Sanchez; J W Curran Journal: Public Health Rep Date: 1990 Mar-Apr Impact factor: 2.792
Authors: E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland Journal: N Engl J Med Date: 1989-09-28 Impact factor: 91.245
Authors: Don C Des Jarlais; Kamyar Arasteh; Holly Hagan; Courtney McKnight; David C Perlman; Samuel R Friedman Journal: Am J Public Health Date: 2009-10 Impact factor: 9.308